Login to Your Account

Depomed Signs $395M Deal with Solvay for Phase III Pain Drug

By Trista Morrison

Monday, November 24, 2008
Depomed Inc. granted an exclusive license to Solvay Pharmaceuticals Inc. for North American rights to DM-1796 (formerly Gabapentin GR) in pain indications. The drug - an extended-release version of the active ingredient in Pfizer Inc.'s marketed seizure and pain drug, Neurontin - is in Phase III trials for postherpetic neuralgia (PHN). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription